Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.

Annals of palliative medicine - 1 Dec 2021

Luo Ying, Yao Bin, Huang Ping, Zhao Yiting, Chen Jun

Abstract excerpt

The lung cancer poses a great threat to the patients' health and social activities. Luckily, epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved the response of patients getting EGFR-mutated non-small cell lung cancer (NSCLC), but the targeted therapy of human epidermal growth factor receptor 2 (HER2) mutations in lung cancer is still being explored; however, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminoquinolines

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 35016465
DOI: 10.21037/apm-21-3468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.PMID 35016465Read ↗

<p>Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report</p>Semantic proximity Read ↗

Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.Semantic proximity Read ↗

[Research Progress of Targeted Therapy for HER2 Gene in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.Semantic proximity Read ↗

Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.Semantic proximity Read ↗

[Role of HER2 in NSCLC].Semantic proximity Read ↗

[Current management and future prospect of HER-2 mutant non-small cell lung cancer].Semantic proximity Read ↗

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.Semantic proximity Read ↗

A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.Semantic proximity Read ↗

[First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion].Semantic proximity Read ↗

A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.